Name: | daclizumab |
---|---|
PubChem Substance ID: | 17397742 |
Synonyms: |
D03639; Daclizumab; 152923-56-3; Daclizumab (USAN); Zenapax (TN); Zenapax
|
Name: | daclizumab |
---|---|
Name (isomeric): | DB00111 |
Drug Type: | biotech |
Synonyms: |
Ig gamma-1 chain C region; Humanized antiCD25; Anti-IL-2
|
Brand: | Zenapax (Hoffmann-La Roche Inc) |
Category: | Immunomodulatory Agents, Immunosuppressive Agents |
CAS number: | 152923-56-3 |
Indication: | Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection |
---|---|
Pharmacology: | Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. |
Mechanism of Action: | Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. |
Biotransformation: | Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes. |
Half Life: | 11-38 days |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|